There are 360 resources available
63P - Activity and safety of first-line treatments for advanced melanoma: a network meta-analysis
Presenter: Andrea Boutros
Session: Poster Display
171P - Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: a multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy
Presenter: Iwona Lugowska
Session: Poster Display
64P - Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with solid tumors and cardiac metastases
Presenter: Amin Nassar
Session: Poster Display
172P - Phase 1 Study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster Display
65P - Atezolizumab plus bevacizumab versus Lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population
Presenter: Margherita Rimini
Session: Poster Display
173P - First-in-human study to evaluate the safety and clinical activity of FS222, a tetravalent bispecific antibody targeting PD-L1 and CD137, in patients with advanced solid tumors
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster Display
66P - Real-world data of first-line chemo-immunotherapy for patients with extensive stage SCLC: A multicentre experience from Switzerland and the UK
Presenter: Laura Moliner Jimenez
Session: Poster Display
174P - First-in-human Study of NGM707, An ILT2/ILT4 Dual Antagonist Antibody in Advanced or Metastatic Solid Tumors: Preliminary Monotherapy Dose Escalation Data
Presenter: Aung Naing
Session: Poster Display
67P - Real Word Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma
Presenter: MARA PERSANO
Session: Poster Display